|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021756,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0087111,
umls-concept:C0278678,
umls-concept:C0543467,
umls-concept:C0871261,
umls-concept:C0936012,
umls-concept:C1253959,
umls-concept:C1513882,
umls-concept:C1514923,
umls-concept:C1522326,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-7-15
|
|
pubmed:abstractText |
The treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients. The current study presents the authors' 20-year experience administering this immunotherapeutic agent.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
113
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
293-301
|
|
pubmed:meshHeading |
pubmed-meshheading:18457330-Adolescent,
pubmed-meshheading:18457330-Adult,
pubmed-meshheading:18457330-Aged,
pubmed-meshheading:18457330-Carcinoma, Renal Cell,
pubmed-meshheading:18457330-Child,
pubmed-meshheading:18457330-Female,
pubmed-meshheading:18457330-Humans,
pubmed-meshheading:18457330-Indoleacetic Acids,
pubmed-meshheading:18457330-Interleukin-2,
pubmed-meshheading:18457330-Male,
pubmed-meshheading:18457330-Middle Aged,
pubmed-meshheading:18457330-National Cancer Institute (U.S.),
pubmed-meshheading:18457330-Retrospective Studies,
pubmed-meshheading:18457330-Survival Rate,
pubmed-meshheading:18457330-Time Factors,
pubmed-meshheading:18457330-United States
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
|
|
pubmed:affiliation |
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
|
|
pubmed:publicationType |
Journal Article
|
